Connect Conference & Show Floor Educational Sessions

View, browse and sort the list of Connect Conference sessions and show floor programming by pass type, track, and format. Please note, all Connect Conference delegates have access to CPhI Connect and InformEx Connect programming. Seating is first come, first serve, so please arrive early to sessions that you would like to attend. Sessions are subject to change.

To learn more about the Connect Conference program, click here.

All SessionsSpeakersMy Schedule
View Sessions As:
  • Bioconjugate and Biotherapeutics: Present and Future - Powered by the American Chemical Society

    • Richard Silva  |  Director of Process Development, ImmunoGen, Inc.
    • Jagath Reddy Junutula  |  Vice President Research & Development, Cellerant Therapeutics, Inc.
    • David Rabuka, Ph.D.  |  Global Head of R&D, Chemical Biology, Catalent Biologics - West (formerly Redwood Bioscience), Catalent Pharma Solutions
    • Robert M. Garbaccio  |  Executive Director, Merck
    Location:  113A
    Track: Drug Development
    Pass Type: Connect Delegate, VIP Attendee - Get your pass now!
    Vault Recording: TBD

    An Antibody-Drug Conjugate Approach to Tissue-Selective Glucocorticoids
    •Investigation of the targeted delivery of glucocorticoids using the ADC modality
    •Discovery of a novel linker design that provided optimal properties for payload conjugation & delivery
    •Lessons learned from investigation of novel linker-payload combinations

    Robert Garbaccio, Executive Director, Merck

    Engineering Antibody Based Designer Drugs for Cancer Therapy
    Antibody therapeutics has revolutionized the treatment of a number of diseases including cancer and inflammation. Antibody engineering methods have been used to improve the efficacy, safety, and half-life of antibody-based drugs to ensure the clinical success. There are about 470 antibody-based therapeutic molecules are currently in the clinical testing, which is a testimony to the applications of antibody engineering that played a major role in expanding this family of large of molecule therapeutics over the past two decades.

    Several applications of antibody engineering will be presented and discussed on how these tools are applied to further expand in developing next generation antibody therapeutics, such as site-specific Antibody Drug Conjugates (ADCs), Bi-specific ADCs, Bi-specific T-cell Engagers (BITE), Immune mobilising monoclonal TCRs Against Cancer (ImmTACs), Chimeric Antigen Receptors (CARs). Oncology drug development recently witnessed an unprecedented improvement in overall survival of patients with the certain type of cancer indications upon treatment with immuno-oncology (IO) molecules, such as anti-PD-1 or anti-PD-L1 antibodies. The presentation highlights the rapidly evolving IO combo trials in conjunction with above described next generation antibody therapeutic molecules that may further raise the bar of overall survival, thus benefiting the cancer patients.

    Jagath Reddy Junutula, Cellerant Therapeutics

    Novel Bioconjugation Strategies Used in Biotherapeutic Development
    This is an overview of chemical methodologies that are currently used in the development of bioetherapeutics, such as antibody-drug conjugates (ADCs), where the proteins are chemically elaborated. The application of these chemistries to the generate site-specifically modified bioconjugates with improved efficacy and safety profiles will be highlighted.

    David Rabuka, PhD, Global Head of R&D, Chemical Biology, Catalent Biologics - West (formerly Redwood Bioscience), Catalent Pharma Solutions